COMMUNIQUÉS West-GlobeNewswire

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
05/10/2026
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for [...]
Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026
05/10/2026
Quarter included presentation at H.C. Wainwright Global Investment Conference, strategic partnership with Alpmed, new regulatory registrations, and continued physician training NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE [...]
4DMT to Host Investor Day on October 21, 2026
05/10/2026
Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; [...]
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
05/10/2026
Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research Company planning NDA [...]
Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins
05/10/2026
Multi-year expansion of the companies’ 2025 agreement to use Gate’s Molecular Gate drug discovery engine to design molecular gate medicines for Lilly targets BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Gate [...]
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
05/10/2026
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in [...]
Cannara étend son entente d’approvisionnement international avec Curaleaf
05/10/2026
MONTRÉAL, 05 oct. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), un producteur verticalement intégré de [...]
Cannara Expands International Supply Agreement with Curaleaf
05/10/2026
MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
05/10/2026
Oncotelic’s AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 05, [...]
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
05/10/2026
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing Milestone [...]
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
05/10/2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
05/10/2026
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily [...]
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
05/10/2026
– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to [...]
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
05/10/2026
~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a [...]
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
05/10/2026
Milestone advances Phase 3 program toward topline results expected in mid 2027 HIGH POINT, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing [...]
Sofwave to Participate in the Jefferies Private MedTech Virtual Summit
05/10/2026
SAN CLEMENTE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
05/10/2026
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the [...]
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
05/10/2026
MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development
05/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today [...]

Pages